Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Cancer neoantigens targeted by adoptive T cell transfer: private no more
Enrico Lugli, … , Pia Kvistborg, Giovanni Galletti
Enrico Lugli, … , Pia Kvistborg, Giovanni Galletti
Published February 4, 2019
Citation Information: J Clin Invest. 2019;129(3):949-951. https://doi.org/10.1172/JCI126295.
View: Text | PDF
Commentary Article has an altmetric score of 5

Cancer neoantigens targeted by adoptive T cell transfer: private no more

  • Text
  • PDF
Abstract

Effector T cell responses directed toward cancer neoantigens mediate tumor regression following checkpoint blockade or adoptive T cell immunotherapy, but are generally “private”, thus requiring considerable effort for their identification. In this issue of the JCI, Malekzadeh et al. show that a fraction of patients with epithelial cancers mount antigen-specific T cell responses to “hot spot” p53 mutations that in some cases are shared among patients. This work suggests that other genes frequently mutated in human cancer can be immunogenic, thus offering a rapid way to screen for cancer neoantigens that can be targeted by subsequent T cell–based therapies.

Authors

Enrico Lugli, Pia Kvistborg, Giovanni Galletti

×

Figure 1

Accelerated neoantigen identification pipeline.

Options: View larger image (or click on image) Download as PowerPoint
Accelerated neoantigen identification pipeline.
A panel of hot spot muta...
A panel of hot spot mutations is tested by target sequencing. Should a known HLA/mutant peptide pair be identified, the patient’s own T cells can be engineered by TCR gene therapy as an off-the-shelf strategy from a previously created library of TCRs. Alternatively, the patient’s TILs can be assessed for neoantigen reactivity by using a collection of mutant peptides from genes frequently mutated in human cancer and by using IFN-γ secretion or 41BB upregulation as a readout. These approaches will decrease the time requested to produce the engineered cell products or vaccine formulations for personalized therapy. Should the patient not harbor hot spot mutations in the tumor, the standard pipeline for neoantigen identification using whole-exome/RNA sequencing and epitope prediction is applied. Assessment of candidate peptides by T cell assays in vitro may be performed as an optional validation step.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Posted by 8 X users
On 3 Facebook pages
33 readers on Mendeley
See more details